Head and Neck TumorsHead and Neck TumorsОпухоли головы и шеи2222-14682411-4634Publishing House ABV Press88710.17650/2222-1468-2023-13-2-35-43ORIGINAL REPORTSОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯPembrolizumab in treatment of head and neck squamous cell carcinoma: clinical cases and real-world practiceПембролизумаб в лечении плоскоклеточного рака головы и шеи: клинические исследования и реальная практикаhttps://orcid.org/0000-0002-6851-9867AlymovYu. V.АлымовЮ. В.
Russian Federation

Yuri vladimirovich Alymov

24 Kashirskoe Shosse, Moscow 115522

Юрий Владимирович Алымов

115522 Москва, Каширское шоссе, 24

hnonco@yvalymov.ruhttps://orcid.org/0000-0002-5421-5985RomanovI. S.РомановИ. С.
Russian Federation

24 Kashirskoe Shosse, Moscow 115522

1 Ostrovityanova St., Moscow 117997

115522 Москва, Каширское шоссе, 24

117997 Москва, ул. Островитянова, 1

https://orcid.org/0000-0002-6796-0968IgnatovaA. V.ИгнатоваА. В.
Russian Federation

24 Kashirskoe Shosse, Moscow 115522

6 Miklukho-Maklaya St., Moscow 117198

115522 Москва, Каширское шоссе, 24

117198 Москва, ул. Миклухо-Маклая, 6

N.N. Blokhin National Research Institute of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииPirogov Russian National Research Medical University, Ministry of Health of RussiaФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииPeoples’ Friendship University of RussiaФГАОУ ВО «Российский университет дружбы народов»1309202313235431209202312092023Copyright ©; 2023, Alymov Y.V., Romanov I.S., Ignatova A.V.Copyright ©; 2023, Алымов Ю.В., Романов И.С., Игнатова А.В.2023Alymov Y.V., Romanov I.S., Ignatova A.V.Алымов Ю.В., Романов И.С., Игнатова А.В.https://creativecommons.org/licenses/by/4.0https://ogsh.abvpress.ru/jour/article/view/887

Recurrent and metastatic head and neck squamous cell carcinoma is a hard-to-treat pathology. median overall survival for standard chemotherapy regimens does not exceed 11 months. One of the factors decreasing treatment effectivenessis frequency of severe adverse events which are observed in every 2nd patient during standard therapy regimens. moreover,  even  if  notable  tumor  regression  is  achieved,  this  effect  is  transient.  Development  of  immunotherapy  drugs, namely pembrolizumab, helps solve these problems. Clinical trials and real-world use of the drug show that in the 1st and 2nd therapy lines for recurrent and metastatic head and neck squamous cell carcinoma, pembrolizumab allows to achieve persistent treatment response, increase overall survival, and decrease the frequency of adverse events.

Рецидивный и метастатический плоскоклеточный рак головы и шеи – патология, плохо поддающаяся лечению. Медиана общей выживаемости при использовании стандартных химиотерапевтических режимов не превышает 11 мес. Одним из факторов, снижающих эффективность лечения, является частота развития тяжелых нежелательных явлений, которые при применении стандартных режимов терапии отмечаются у каждого второго пациента. более того, даже при достижении выраженной регрессии опухоли при использовании стандартной химиотерапии эффект кратковременен. появление иммуноонкологических препаратов, в частности пембролизумаба, способствует решению этих проблем. Клинические исследования и практическое применение данного препарата демонстрируют, что в 1-й или 2-й линии лекарственной терапии рецидивного и метастатического плоскоклеточного рака головы и шеи пембролизумаб позволяет добиться стойкого ответа на лечение, повысить показатели общей выживаемости и снизить частоту развития побочных эффектов.

immunotherapydrug treatmentpembrolizumabpembroriacarcinomahead and necksquamous cell carcinomaиммунотерапиялекарственное лечениепембролизумабпемброриакарциномаголова и шеяплоскоклеточный ракThe publication was prepared with the sponsorship of BIOCAD.Публикация подготовлена при спонсорской поддержке компании BIOCAD.Malignant neoplasms in Russia in 2017 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinsky, G.V. Petrova. Moscow: P.A. Herzen Moscow State Medical Research Institute – branch of the Federal State Budgetary Institution "NMIC of Radiology" of the Ministry of Health of Russia, 2018. (In Russ.).Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018El-Naggar A.K., Chan J.K.C., Grandis J.R., Slootweg P.J. WHO classification of head and neck tumours. 2017. Available at: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Head-And-Neck-Tumours-2017El-Naggar A.K., Chan J.K.C., Grandis J.R., Slootweg P.J. WHO classification of head and neck tumours. 2017. Available at: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Head-And-Neck-Tumours-2017Sanderson R.J., Ironside J.A. Squamous cell carcinomas of the head and neck. BMJ 2002;325(7368):822–7. DOI: 10.1136/bmj.325.7368.822Sanderson R.J., Ironside J.A. Squamous cell carcinomas of the head and neck. BMJ 2002;325(7368):822–7. DOI: 10.1136/bmj.325.7368.822Pignon J.P., le Maître A., Maillard E., Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92(91):4–14. DOI: 10.1016/j.radonc.2009.04.014Pignon J.P., le Maître A., Maillard E., Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92(91):4–14. DOI: 10.1016/j.radonc.2009.04.014Bernier J., Domenge C., Ozsahin M. et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945–52. DOI: 10.1056/NEJMoa032641Bernier J., Domenge C., Ozsahin M. et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945–52. DOI: 10.1056/NEJMoa032641Cooper J.S., Pajak T.F., Forastiere A.A. et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350(19):1937–44. DOI: 10.1056/NEJMoa032646Reeves T.D., Hill E.G., Armeson K.E., Gillespie M.B. Cetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the data. Otolaryngol Head Neck Surg 2011;144(5):676–84. DOI: 10.1177/0194599811399559Jacobs C., Lyman G., Velez-García E. et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10(2):257–63. DOI: 10.1200/JCO.19Grau J.J., Caballero M. et al. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta Otolaryngol 2009;129(11):1294–9. DOI: 10.3109/00016480802590451Catimel G., Verweij J., Mattijssen V. et al. Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994;5(6):533–7. DOI: 10.1093/oxfordjournals.annonc.a058908Guardiola E., Peyrade F., Chaigneau L. et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 2004;40(14):2071–6. DOI: 10.1016/j.ejca.2004.05.019Martinez-Trufero J., Isla D., Adansa J.C. et al. Phase II study of capecita-bine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. Br J Cancer 2010;102(12):1687–91. DOI: 10.1038/sj.bjc.6605697Guntinas-Lichius O., Appenrodt S., Veelken F., Krug B. Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer. Laryngoscope 2006;116(4):613–8. DOI: 10.1097/01.mlg.0000208366.34683.58Gibson M.K., Li Y., Murphy B. et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23(15):3562–7. DOI: 10.1200/JCO.2005.01.057Vermorken J.B., Mesia R., Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116–27. DOI: 10.1056/NEJMoa0802656Vermorken J.B., Mesia R., Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116–27. DOI: 10.1056/NEJMoa0802656Grandis J., Tweardy D. Elevated levels of transforming growth factor α and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53(15):3579–84.Baselga J., Trigo J.M., Bourhis J. et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23(24):5568–77. DOI: 10.1200/JCO.2005.07.119Baselga J., Trigo J.M., Bourhis J. et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23(24):5568–77. DOI: 10.1200/JCO.2005.07.119Herbst R.S., Arquette M., Shin D.M. et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23(24):5578–87. DOI: 10.1200/JCO.2005.07.120Vermorken J.B., Trigo J., Hitt R. et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25(16):2171–7. DOI: 10.1200/JCO.2006.06.7447León X., Hitt R., Constenla M. et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol) 2005;17(6):418–24. DOI: 10.1016/j.clon.2005.02.014Guigay J., Fayette J., Mesia R. et al. TPExtreme randomized trial: TPEx versus extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol 2019;37(15):6002.Badoual C., Hans S., Merillon N. et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013;73(1):128–38. DOI: 10.1158/0008-5472.CAN-12-2606Badoual C., Hans S., Merillon N. et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013;73(1):128–38. DOI: 10.1158/0008-5472.CAN-12-2606Zandberg D.P., Strome S.E. The role of the PD-L1: PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol 2014;50:627–32. DOI: 10.1016/j.oraloncology.2014.04.003Cohen E.E.W., Soulières D., Le Tourneau C. et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019;393(10167):156–67. DOI: 10.1016/S0140-6736(18)31999-8Cohen E.E.W., Soulières D., Le Tourneau C. et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019;393(10167):156–67. DOI: 10.1016/S0140-6736(18)31999-8Harrington K.J., Soulières D., Le Tourneau C. et al. Quality of Life with pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma: KEYNOTE-040. J Natl Cancer Inst 2021;113(2):171–81. DOI: 10.1093/jnci/djaa063Soulieres D., Harrington K.J., Le Tourneau C. et al. 658MO Pembro lizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040. Ann Oncol 2022; 33(7):S843.Burtness B., Harrington K.J., Greil R. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;23;394(10212):1915–28. DOI: 10.1016/S0140-6736(19)32591-7Burtness B., Harrington K.J., Greil R. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;23;394(10212):1915–28. DOI: 10.1016/S0140-6736(19)32591-7Rischin D., Harrington K.J., Greil R. et al. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol 2019;37(Suppl. 15):6000. DOI: 10.1200/JCO.2019.37.15_suppl.6000Harrington K.J., Burtness B., Greil R. et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. J Clin Oncol 2023;41(4):790–802. DOI: 10.1200/JCO.21.02508Harrington K.J., Burtness B., Greil R. et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. J Clin Oncol 2023;41(4):790–802. DOI: 10.1200/JCO.21.02508Tahara M., Greil R., Rischin D. et al. 659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/ metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048. Ann Oncol 2022;33(Suppl. 7): S295–322. DOI: 10.1016/annonc/annonc1056Tahara M., Greil R., Rischin D. et al. 659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/ metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048. Ann Oncol 2022;33(Suppl. 7): S295–322. DOI: 10.1016/annonc/annonc1056Chen W.C., Chu P.Y., Lee Y.T. et al. Pembrolizumab for recurrent/ metastatic head and neck squamous cell carcinoma in an Asian population. Medicine (Baltimore) 2017;96(52):e9519. DOI: 10.1097/MD.0000000000009519He Y., Zeng J., Wei Z. et al. Comparison of second-line treatments for patients with platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and bayesian network meta-analysis. Cancers (Basel) 2022;14(18):4472. DOI: 10.3390/cancers14184472He Y., Zeng J., Wei Z. et al. Comparison of second-line treatments for patients with platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and bayesian network meta-analysis. Cancers (Basel) 2022;14(18):4472. DOI: 10.3390/cancers14184472Wagner S.M., Magnes T., Melchardt T. et al. Real-world data of palliative first-line checkpoint inhibitor therapy for head and neck cancer. Anticancer Res 2023;43(3):1273–82. DOI: 10.21873/anticanres.16274Sano D., Tokuhisa M., Takahashi H. et al. Real-world therapeutic outcomes of the pembrolizumab regimen as first-line therapy for recurrent/metastatic squamous cell carcinoma of the head and neck: a single-center retrospective cohort study in Japan. Anticancer Res 2022;42(9):4477–84. DOI: 10.21873/anticanres.15948Sano D., Tokuhisa M., Takahashi H. et al. Real-world therapeutic outcomes of the pembrolizumab regimen as first-line therapy for recurrent/metastatic squamous cell carcinoma of the head and neck: a single-center retrospective cohort study in Japan. Anticancer Res 2022;42(9):4477–84. DOI: 10.21873/anticanres.15948Bolotina L.V., Vladimirova L.Yu., Dengina N.V. et al. Practical recommendations for the treatment of malignant tumors of the head and neck. Zlokachestvennye opuholi: Prakticheskie rekomendacii RUSSCO = Malignant Tumors: Practical Recommendations of RUSSCO #3s2. 2022;12:94–112. (In Russ.).Болотина Л.В., Владимирова Л.Ю., Деньгина Н.В. и др. Практические рекомендации по лечению злокачественных опухолей головы и шеи. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2022;12:94–112.